Table 2.
Health outcomes for patients who received ceftaroline
| Variable | All (n=764) |
Skin (n=307) |
Sepsis (n=233) |
Osteo (n=193) |
Diab foot (n=170) |
Pneumonia (n=124) |
Bact (n=87) |
Endo (n=46) |
Mening (n=18) |
Device (n=15) |
|---|---|---|---|---|---|---|---|---|---|---|
| Hosp. LOS, median (IQR) | 5 (3–12) | 5 (3–9) | 6 (3–15) | 5 (3–15) | 5 (3–7) | 8 (3–18) | 8 (3–18) | 7 (3–14) | 9 (4–34) | 10 (3–19) |
| Hosp. Mortality, % | 5% | 2% | 9% | 3% | 1% | 13% | 6% | 11% | 6% | 13% |
| 30d Hosp. Readmit, % | 33% | 36% | 36% | 35% | 38% | 30% | 48% | 28% | 44% | 40% |
Hosp. LOS: hospital length of stay; IQR: interquartile range; Hosp. mortality: hospital mortality